Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitric oxide in primary headaches.

L L Thomsen1, J Olesen

  • 1Department of Neurology, The Lundbeck Institute, Skodsborg, Denmark. llt@lundbeck.com

Current Opinion in Neurology
|May 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache.

The journal of headache and pain·2019
Same author

Pilot Experience with an External Quality Assurance Scheme for Acylcarnitines in Plasma/Serum.

JIMD reports·2016
Same author

European Headache Federation consensus on technical investigation for primary headache disorders.

The journal of headache and pain·2016
Same author

Prevalence of migraine in persons with the 3243A>G mutation in mitochondrial DNA.

European journal of neurology·2015
Same author

Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).

Vox sanguinis·2015
Same author

Impact of training status on LPS-induced acute inflammation in humans.

Journal of applied physiology (Bethesda, Md. : 1985)·2015
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Nitric oxide (NO) may be a key molecule in primary headaches like migraine. Evidence suggests NO release triggers headache pain, and NO inhibitors show promise for treatment.

Area of Science:

  • Neuroscience
  • Vascular Biology
  • Pain Research

Background:

  • The precise molecular mechanisms of primary headaches, including migraine, cluster headache, and tension-type headache, remain unclear.
  • Nitric oxide (NO), a signaling molecule, is implicated due to its role in vasodilation and neurotransmission.
  • Studies involving glyceryl trinitrate and histamine suggest NO's involvement in headache induction.

Purpose of the Study:

  • To review the biological role of nitric oxide (NO) as a messenger molecule.
  • To present updated scientific evidence supporting NO's key role in primary headaches.
  • To explore the potential of NO modulation for headache treatment.

Main Methods:

  • Review of existing scientific literature on nitric oxide biology and headache mechanisms.

Related Experiment Videos

  • Analysis of studies investigating NO donors (glyceryl trinitrate) and histamine-induced headaches.
  • Examination of pilot trial data for nitric oxide synthase inhibitors in headache treatment.

    • Main Results:

    • Evidence suggests nitric oxide release from vasculature, nerves, or brain tissue is a critical trigger for spontaneous headache pain.
    • Pilot trials indicate that inhibiting nitric oxide synthase is effective for both acute migraine attacks and chronic tension-type headaches.
    • These findings highlight NO as a significant molecular player in headache pathophysiology.

    Conclusions:

    • Nitric oxide is strongly implicated as a key molecular mediator in primary headaches.
    • Targeting nitric oxide pathways, particularly through synthase inhibition, offers a promising new avenue for pharmacological headache therapies.
    • Further research into NO's precise role could lead to more effective treatments for debilitating headache conditions.